Courage Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Courage Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-934,462	Closed	-$1.57M	–	19
2016 Q3	$1.57M	Buy	934,462 +484,462	+108%	+$594K	0.61%	9
2016 Q2	$473K	Buy	+450,000	New	+$435K	0.26%	11

Other funds holding ATRS

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Courage Capital Management's ATRS Position: Q4 2016 in Review

Courage Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q4 2016, closing a stake of 934,462 shares — an estimated $1.57M sold.

Courage Capital Management first reported a position in ATRS in Q2 2016 and held it in 2 quarters. The position peaked at $1.57M in Q3 2016. 71 funds tracked by Wall St. Rank hold ATRS as of Q4 2016.

Courage Capital Management reported no remaining Antares Pharma, Inc. position as of Q4 2016 after selling out during the quarter.
Courage Capital Management sold 934,462 Antares Pharma, Inc. shares in Q4 2016, an estimated $1.57M.
Courage Capital Management first reported a position in Antares Pharma, Inc. in Q2 2016 and held it in 2 quarters.
Courage Capital Management's Antares Pharma, Inc. position peaked at $1.57M in Q3 2016.
71 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2016.

Based on Courage Capital Management's 13F filing for Q4 2016, filed 10 Feb 2017.